The long-term safety of exposure to anti-tumor necrosis factor (anti-TNF ) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with infl ammatory bowel disease (IBD) who were exposed to anti-TNF drugs in utero with that of children who were not exposed to the drugs.
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INTRODUCTION
Most patients with infl ammatory bowel disease (IBD) are aff ected during their peak reproductive years, when many female patients aff ected by Crohn's disease or ulcerative colitis want to have children. Although a diagnosis of IBD does not pose a risk to pregnancy, it has been shown that active disease or a disease fl are-up is associated with poor obstetrical outcomes ( 1-4 ). As a result, eff ective control of disease activity is vital both before conception and during pregnancy.
Anti-tumor necrosis factor α (anti-TNFα ) drugs have been increasingly used for the treatment of IBD ( 5 ). Th erefore, many women wishing to become pregnant may be exposed to these drugs. In this respect, taking anti-TNFα drugs during pregnancy has been considered safe in several registries and observational studies ( 6 ) . Nevertheless, their presumed safety is based on shortterm data (at delivery or during the fi rst few months postpartum).
Th e human placenta seems to be impermeable to all antibodies from the maternal immune system except immunoglobulin G (IgG) ( 7 ) . Infl iximab, adalimumab, and golimumab are IgG1 monoclonal antibodies, whereas certolizumab is a Fab fragment of IgG1 antibody. Materno-fetal transfer of IgG takes place via binding to a specifi c receptor known as the neonatal Fc or Brambell receptor (FcRn). Th e FcRn of placental syncytiotrophoblasts is not detected before 14 weeks of gestation ( 8 ) .
Case series have reported clinically signifi cant infl iximab and adalimumab levels in cord blood when these drugs were administered at the end of the second trimester or during the third trimester, although this was not the case for certolizumab pegol ( 9 ) . A number of case reports indicate that placental transfer of infl iximab leads to prolonged exposure in the neonate. Indeed, serum levels in neonates are oft en higher than those in maternal serum and remain detectable up to 6 months aft er birth, probably as a result of the immaturity of the reticuloendothelial system, which leads to slow antibody clearance ( 10 ) . However, the eff ects of these high drug levels on the developing immune system are unknown.
Th e initial results of two series showed that children with high drug levels did not seem to have an increased risk of infection in their fi rst year of life and that they had a normal response to inactivated vaccines ( 1, 11 ) . In newborns exposed to anti-TNFα in utero , high levels of the drug are present during a period that is crucial for the development of the immune system.
In summary, anti-TNFα treatment during pregnancy seems to be relatively safe in the short term. However, the long-term eff ects of intrauterine exposure to anti-TNFα drugs remain uncertain. Th erefore, the primary aim of the present study was to compare the relative risk of severe infections in children from mothers with IBD who have been exposed to anti-TNFα drugs in utero with that of children who were not exposed. Th e secondary aims were to compare the prevalence of malformations in children exposed to anti-TNFα drugs in utero with that of children who were not exposed, to evaluate the relative risk of developing neoplasm in children exposed to anti-TNFα drugs, and to ascertain the relative risk of complications in children exposed to anti-TNFα drugs.
METHODS
We designed a retrospective multicenter cohort study of children born to women diagnosed with IBD and treated with anti-TNFα drugs during pregnancy or the 3 months before conception. In order to identify the long-term eff ects of these drugs on off spring, we also included a non-exposed cohort with children born to women with IBD who did not receive anti-TNFα drugs during their pregnancies. Th e principal variable was the risk of severe infection, defi ned as an infection that led the child to be admitted to hospital. Children were followed from birth to the date of inclusion, when mothers were contacted (2014 in most cases). In order to minimize heterogeneity in the management of IBD, inclusion was limited to pregnancies occurring aft er 1999, when infl iximab was approved for IBD in Europe. Practitioners specialized in IBD identifi ed women from their practice who received or did not receive anti-TNFα drugs for IBD during their pregnancy. In order to avoid selection bias, clinicians were asked to systematically review their databases in order to identify patients who met the inclusion criteria. In addition, clinicians were asked to contact women whose reproductive age (15-50 years) was within the study timeframe. Th e study was approved by the ethics com-
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mittees of each participating center and by the Spanish Agency of Medicines and Medical Devices.
Study population -Exposed cohort: children from mothers treated with anti-TNFα drugs either in monotherapy or in combination with thiopurines at any time during pregnancy or during the 3 months before conception. -Non-exposed cohort: children from mothers not treated with anti-TNFα drugs or thiopurines at any time during pregnancy or during the 3 months before conception.
Data collection
Women who had been pregnant within the study timeframe at each participating center were contacted to obtain information about the development of their children. Data were obtained from the medical records at the participating center and medical reports on the delivery. In addition, the mothers provided information of the children's admissions to hospital. In the case of missing data, the mothers were asked to obtain them. Finally, cases with relevant missing data were ruled out aft er contacting the investigator. Th e variables included in the database were IBD type, age at diagnosis of IBD, age at conception, comorbidities, smoking habit and alcohol consumption during pregnancy, surgical interventions due to IBD, folic acid supplementation during pregnancy and conception, medical treatment during conception, pregnancy and breastfeeding (including all drugs, whether associated or not with IBD), complications during pregnancy and delivery, newborn complications, breastfeeding, infant allergies, vaccinations, and infant complications until the end of followup (e.g., severe infections and neoplasms). Th e data collected on severe infections were type of infection, date of infection, length of stay, and need for admission to the intensive care unit. Study data were collected and managed using an electronic data capture tool (Research Electronic Data Capture (REDCap)), which is hosted at Asociación Española de Gastroenterología (AEG; www. aegastro.es ) ( 12 ), a non-profi t scientifi c and medical society focusing on gastroenterology. AEG provided this service free of charge, with the sole aim of promoting independent investigator-driven research. REDCap is a secure, web-based application designed to support data capture for research studies that provides the following: (i) an intuitive interface for validated data entry; (ii) audit trails for tracking data manipulation and export procedures; (iii) automated export procedures for seamless data downloads to common statistical packages; and (iv) procedures for importing data from external sources.
Defi nitions
-Complications: any complication recorded during pregnancy or delivery or in the newborn. -Complication during pregnancy: at least one of the following outcomes during pregnancy: growth retardation; infection; eclampsia; placenta previa; chorioamnionitis; or abruptio placenta.
-Complication during delivery: at least one complication during delivery, such as instrumental delivery, caesarean section, or preterm delivery. -Newborn complications: at least one complication in the newborn, such as congenital malformations, admission to the intensive care unit, low birth weight, or low Apgar score. -Severe infection: an infection that led the child to be admitted to hospital at any time during follow-up. -Preterm delivery: delivery before week 37 of gestation ( 3, 4 ) . -Low birth weight: <2,500 mg ( 3,4 ). -IBD activity: IBD activity was assessed before conception and during each trimester of gestation based on the Harvey-Bradshaw index for Crohn's disease and the Partial Mayo Score for ulcerative colitis. Th e medical records were consulted to obtain the variables needed to calculate the score. -Low Apgar score: Apgar scores lower than 7 were considered low, and scores of 7 or higher were considered normal at 10 min aft er birth ( 13 ) .
Statistical analysis
Quantitative variables were expressed as the mean and s.d. or the median and interquartile range, depending on whether they were normally distributed or not. Categorical variables were expressed as percentages and 95% confi dence intervals. Means were compared using the t -test for independent samples or the MannWhitney test (according to the distribution of data). Categorical variables were compared using the χ 2 -test and Fisher exact test or the Wilcoxon rank-sum test according to the distribution of data. Statistical signifi cance was set at P <0.05 for the overall comparison of the cohorts (non-exposed and exposed to anti-TNFα drugs).
Th e cumulative incidence of severe infection aft er birth was estimated using Kaplan-Meier curves, which were compared using the log-rank test. Cox regression analysis was performed to identify independent predictors of severe infection. In the Cox regression model, the dependent variable was the presence of severe infection, and the independent variables were those which were considered clinically relevant (e.g., type of IBD, maternal age at conception, consumption of toxic substances during pregnancy, IBD activity at the moment of conception, disease activity during pregnancy, low birth weight, prematurity, and exposure to anti-TNFα drugs) and those which reached statistical signifi cance in the univariate analysis.
RESULTS
A total of 841 children were included. Of these, 388 (46%) had been exposed to anti-TNFα drugs in utero and 453 (54%) had not been exposed. Th e demographic characteristics of the children's mothers are summarized in Table 1 . Of note, the proportion of Crohn's disease, previous surgery, and smoking habit was higher among mothers from the exposed cohort. Of the children exposed to anti-TNFα drugs, 57.4% had been exposed to infl iximab, 42.3% to adalimumab, and 0.3% to certolizumab pegol ( Table 2 ) . Ninety-nine (25%) had also been exposed to thiopurines.
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Th e overall proportion of complications during pregnancy was similar in the exposed and non-exposed cohorts (14.9% vs. 17.7%, P =0.29). However, the proportion of infections in mothers treated with anti-TNFα drugs during gestation was higher in the exposed cohort (4.1% vs. 0.9%, P =0.002). Other complications, such as premature rupture of membranes, chorioamnionitis, placenta previa, eclampsia, and fetal growth retardation, were equally distributed in both groups ( Table 3 ) .
On the other hand, the proportion of complications during delivery was signifi cantly higher in the exposed cohort (57.5% vs. 43.5%, P <0.01). As for type of complications, the proportion of cesarean sections was signifi cantly higher in the exposed group (44% vs. 32%, P <0.01). When cesarean section was not considered a complication (i.e., planned and emergency), the proportion of delivery complications was still higher in the exposed group (20.4% vs. 14.6%, P =0.02). Th e distribution of other complications, such as instrumental delivery or preterm delivery, was similar between both groups ( Table 3 ) .
Finally, the proportion of children with complications aft er birth was signifi cantly higher in the exposed cohort (19% vs. 10.5%, P <0.01). Similarly, the proportion of children admitted to the intensive care unit was signifi cantly higher in the exposed cohort (7% vs. 3.1%, P <0.01), as was the prevalence of children with low birth weight (9.8% vs. 5%, P <0.01). Other complications, such as congenital malformation or low Apgar score, were equally distributed between the groups.
Severe infections in the offspring during follow-up
A total of 90 children developed severe infection during followup, 46 (12%) in the exposed cohort and 44 (9.7%) in the nonexposed cohort ( P =0.3), although all of the infections resolved. In addition, 3 (3%) of the 90 children developed two severe infections during follow-up, and 2 children (2%) developed three severe infections, although all of the infections resolved. Median follow-up time in the overall group was 68 months (range, 13-216 moths): 68 months (range, 13-216 months) in the non-exposed group, and 47 months (range, 9-202 months) in the exposed a Delivery-related complications excluding cesarean section: 20.4% exposed cohort vs. 14.6% non-exposed cohort ( P =0.02).
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As expected, the most prevalent infections were respiratory infections, followed by gastrointestinal infections and urinary infections ( Table 4 ) . With respect to time of onset of the infection, median age at diagnosis of severe infection was 8.2 months in the exposed group (range, 0-80 months) and 7.5 months (range, 0-72 months) in the non-exposed group ( P >0.05). In particular, 66% of the severe infections in the exposed cohort and 64% of those in the non-exposed cohort occurred within the fi rst year of life.
Mean length of stay due to severe infection was 7.5 days in the exposed group and 6.3 days in the non-exposed group ( P >0.05). In addition, the need for admission to the intensive care unit owing to severe infection was similar in both cohorts ( P >0.05). Furthermore, the length of admission in the intensive care unit did not diff er between the groups ( P >0.05).
In the univariate analysis, only preterm delivery was associated with a higher risk of severe infection aft er birth ( P <0.001; Figure  2 ). No other variables (e.g., intrauterine exposure to thiopurines, active disease during pregnancy, maternal smoking, or exposure to anti-TNFα drugs (including exposure during the third trimester in comparison with non-exposure and, within the exposed cohort, exposure during the third trimester in comparison with children not exposed during the third trimester)) were associated with a higher risk of severe infection. Th e association remained signifi cant in the multivariate analysis ( Table 5 ). Aft er adjustment for low birth weight, only preterm delivery was associated with a higher risk of infection (hazard ratio, 2.5; 95% confi dence interval, 1.5-4.3).
Severe infection in children exposed to both thiopurines and anti-TNF drugs
Ninety-nine children in the exposed group (25%) had received combination therapy with anti-TNF and thiopurines in utero .
cohort. Th e incidence rate of infection was similar between both groups ( Figure 1 ): 2.8% per person-year in the exposed cohort and 1.6% per person-year in the non-exposed cohort ( P =0.2). 
N , number of children. Log-rank<0.001 Figure 2 . Survival curves for the cumulative incidence of severe infections by preterm delivery.
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Eleven children (11%) in the combination group and 35 (12%) in the anti-TNFα monotherapy group developed a severe infection. Th e prevalence of severe infections was similar among children exposed to anti-TNFα in monotherapy and in those whose therapy was combined with thiopurines (12% vs. 11%, P >0.05). Moreover, the cumulative incidence of severe infection was similar in both groups.
Other outcomes during follow-up
No children developed neoplasms during follow-up. Th e proportion of children who were not vaccinated according to local guidelines was signifi cantly higher in the exposed cohort (6% vs. 1.3%, P <0.01). A total of 41 children in the exposed cohort (10.6%) developed allergies during follow-up, as did 36 (7.9%) in the non-exposed cohort ( P >0.05).
DISCUSSION
Th e results of the present study show that exposure to anti-TNFα drugs in utero does not increase the risk of severe infections in children born to mothers with IBD. To our knowledge, this is the largest cohort of children exposed in utero to anti-TNFα drugs (~400 children) and with the longest follow-up (mean of 4 years). We found that the incidence rate of severe infection was 2.8% per person-year in the exposed cohort and 1.6% per person-year in the non-exposed cohort. Data about the incidence rate of severe infection in children in the general population are scarce. An epidemiological study performed in the Valencia region of eastern Spain estimated that the incidence rate of admission due to infections in a pediatric population was 1.7% per patient-year, which was similar to the fi gure we found in the non-exposed cohort ( 14 ) . To date, most studies on the safety of anti-TNFα drugs during pregnancy have focused on gestation and delivery or, in some cases, on the immediate postpartum ( 6 ) . Data from those studies support the safety of anti-TNFα drugs, at least in the short term. However, caution about the use of these drugs during pregnancy is advised owing to the lack of data on the long-term impact in children exposed to anti-TNFα drugs.
Many studies have demonstrated the presence of detectable anti-TNFα drugs in the serum of infants born to mothers receiving these agents during pregnancy ( 9, 15, 16 ) In fact, median cord blood drug concentration seems to be higher than maternal serum drug concentration. In addition, an inverse correlation has been reported between the time since the most recent drug exposure and both cord blood and maternal blood concentration ( 9, 15 ) . Immaturity of the reticuloendothelial system leading to slow antibody clearance is probably responsible for this eff ect ( 15, 17 ) .
TNFα plays an important role in embryonic and fetal development. Increased embryonic death and structural defects have been detected in TNFα knockout mice compared with the wild type ( 18 ) . However, blockade of TNFα by antagonists, as opposed to gene knockout, may have diff erent eff ects on the developing fetus. Th e role of TNFα in human pregnancy is not fully understood. During fetal development, the TNFα superfamily members lymphotoxin-α and -β play an important role in the development and organization of secondary lymphoid tissues ( 19 ) .
It is well known that anti-TNFα agents are unlikely to cross the placenta in the fi rst trimester, although they do so very effi ciently in the late second and third trimesters ( 20 ) . Th is may protect the infant from exposure during the crucial period of organogenesis in the fi rst trimester. However, placental transfer in the third trimester means that anti-TNFα agents can be present in the infant for several months aft er delivery, thus raising concerns about immune system development and the consequent risk of infections.
In this respect, preliminary results from the PIANO study were presented at Digestive Diseases Week in 2012 ( 21 ) . In this prospective cohort study performed at 30 IBD centers in the United States, patients were classifi ed according to exposure between conception and delivery. Women were contacted during each trimester, at delivery, and at 4, 9, and 12 months aft er delivery. At the time of the sub-analysis, 102 women had been treated with anti-TNFα drugs during pregnancy, and 59 women had received both thiopurines and anti-TNFα agents. Th e authors reported that the use of thiopurines and anti-TNFα agents was not associated with an increased rate of complications, such as spontaneous abortion, congenital anomalies, preterm birth, intrauterine growth retardation, and cesarean section. However, a signifi cant increase in the frequency of infections was recorded in infants aged 9-12 months in the combination therapy group (mothers receiving both thiopurines and anti-TNFα agents) compared with the unexposed group. As the anti-TNFα drug is generally no longer detectable in infants aged 9-12 months, the authors stated that this fi nding might suggest dysfunctional immune development and thus merits further investigation.
In our cohort study, children in the exposed cohort were born from mothers with more aggressive IBD: more had Crohn's disease, the prevalence of previous surgery due to IBD was also higher, and more intensive therapy was necessary to control disease activity (such as anti-TNFα with or without thiopurines). Nevertheless, the incidence rate of severe infection was similar in the exposed and non-exposed cohorts. Only preterm delivery (adjusted for low birth weight) was signifi cantly associated with a higher risk of infection. However, neither treatment with anti-TNFα drugs nor combined therapy with thiopurines was signifi cantly associated with a higher risk of severe infection. Of note, given that only live births were included in our study, the risk of complications during pregnancy and delivery could not be assessed.
We were unable to fi nd any diff erence between the exposed and non-exposed groups with respect to severity of infection. In this Chaparro et al.
Our study also has a series of strengths. It is the largest study to date to assess the long-term impact of anti-TNFα drugs on the off spring of mothers with IBD. It also has the longest follow-up period. Despite its retrospective design, it is obvious that a prospective study with a suffi ciently large sample would take many years to provide long-term information about the impact of anti-TNFα drugs on the risk of infections in children. In addition, the risk of recall bias of the principal variable (severe infection) should be low, as parents can easily remember whether their children have been admitted to hospital. Furthermore, relevant information such as complications of pregnancy or delivery, and details about admissions due to infection could easily be found in the medical reports at discharge.
In conclusion, our large observational study found that exposure to anti-TNFα drugs during pregnancy in mothers with IBD did not increase the long-term risk of severe infection in off spring. Preterm birth increases the risk of severe infection in infants born to women with IBD. Th e risk of severe infection does not seem to be higher in children exposed to both anti-TNFα and thiopurines, although this association should be investigated further, as our study was not suffi ciently powered to evaluate the issue.
